Immix Biopharma Stock Forward View - Double Exponential Smoothing
| IMMX Stock | USD 6.21 0.38 6.52% |
Immix Stock outlook is based on your current time horizon.
The value of RSI of Immix Biopharma's stock price is slightly above 61. This usually indicates that the stock is rather overbought by investors at this time. The main point of the Relative Strength Index (RSI) is to track how fast people are buying or selling Immix, making its price go up or down. Momentum 61
Buy Extended
Oversold | Overbought |
Using Immix Biopharma hype-based prediction, you can estimate the value of Immix Biopharma from the perspective of Immix Biopharma response to recently generated media hype and the effects of current headlines on its competitors.
The Double Exponential Smoothing forecasted value of Immix Biopharma on the next trading day is expected to be 6.23 with a mean absolute deviation of 0.25 and the sum of the absolute errors of 14.69. Immix Biopharma after-hype prediction price | USD 6.21 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Immix Biopharma to cross-verify your projections. For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.Immix Biopharma Additional Predictive Modules
Most predictive techniques to examine Immix price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Immix using various technical indicators. When you analyze Immix charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Immix Biopharma Double Exponential Smoothing Price Forecast For the 3rd of February
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Immix Biopharma on the next trading day is expected to be 6.23 with a mean absolute deviation of 0.25, mean absolute percentage error of 0.10, and the sum of the absolute errors of 14.69.Please note that although there have been many attempts to predict Immix Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Immix Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Immix Biopharma Stock Forecast Pattern
| Backtest Immix Biopharma | Immix Biopharma Price Prediction | Research Analysis |
Immix Biopharma Forecasted Value
In the context of forecasting Immix Biopharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Immix Biopharma's downside and upside margins for the forecasting period are 0.05 and 12.41, respectively. We have considered Immix Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Immix Biopharma stock data series using in forecasting. Note that when a statistical model is used to represent Immix Biopharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0213 |
| MAD | Mean absolute deviation | 0.2491 |
| MAPE | Mean absolute percentage error | 0.0505 |
| SAE | Sum of the absolute errors | 14.6948 |
Predictive Modules for Immix Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Immix Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Immix Biopharma After-Hype Price Density Analysis
As far as predicting the price of Immix Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Immix Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Immix Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Immix Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Immix Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Immix Biopharma's historical news coverage. Immix Biopharma's after-hype downside and upside margins for the prediction period are 0.03 and 12.39, respectively. We have considered Immix Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Immix Biopharma is unstable at this time. Analysis and calculation of next after-hype price of Immix Biopharma is based on 3 months time horizon.
Immix Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Immix Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Immix Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Immix Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
1.21 | 6.18 | 0.00 | 0.28 | 0 Events / Month | 2 Events / Month | Uncertain |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
6.21 | 6.21 | 0.00 |
|
Immix Biopharma Hype Timeline
Immix Biopharma is currently traded for 6.21. The entity stock is not elastic to its hype. The average elasticity to hype of competition is 0.28. Immix is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is insignificant. The immediate return on the next news is expected to be very small, whereas the daily expected return is currently at 1.21%. %. The volatility of related hype on Immix Biopharma is about 2686.96%, with the expected price after the next announcement by competition of 6.49. About 22.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.75. Immix Biopharma had not issued any dividends in recent years. Given the investment horizon of 90 days the next expected press release will be uncertain. Check out Historical Fundamental Analysis of Immix Biopharma to cross-verify your projections. For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.Immix Biopharma Related Hype Analysis
Having access to credible news sources related to Immix Biopharma's direct competition is more important than ever and may enhance your ability to predict Immix Biopharma's future price movements. Getting to know how Immix Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Immix Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| COYA | Coya Therapeutics Common | 0.00 | 0 per month | 0.00 | (0.10) | 4.69 | (5.27) | 18.45 | |
| WHWK | Whitehawk Therapeutics | 0.00 | 0 per month | 3.33 | 0.10 | 6.98 | (5.26) | 21.49 | |
| ONCY | Oncolytics Biotech | 0.04 | 9 per month | 0.00 | (0.05) | 8.55 | (8.40) | 27.19 | |
| ZNTL | Zentalis Pharmaceuticals Llc | 0.00 | 0 per month | 3.89 | 0.16 | 17.36 | (6.68) | 48.58 | |
| SRZN | Surrozen | 2.17 | 10 per month | 4.32 | 0.14 | 13.34 | (6.75) | 34.29 | |
| ATOS | Atossa Genetics | 0.07 | 8 per month | 0.00 | (0.21) | 6.75 | (8.77) | 19.84 | |
| TIL | Instil Bio | 0.00 | 0 per month | 0.00 | (0.13) | 6.59 | (9.97) | 55.58 | |
| PLRX | Pliant Therapeutics | 0.02 | 7 per month | 0.00 | (0.17) | 4.58 | (6.71) | 22.72 | |
| MGNX | MacroGenics | 0.00 | 0 per month | 3.20 | 0.08 | 6.83 | (5.18) | 24.44 | |
| ORMP | Oramed Pharmaceuticals | 0.00 | 0 per month | 1.91 | 0.22 | 6.98 | (3.49) | 17.67 |
Other Forecasting Options for Immix Biopharma
For every potential investor in Immix, whether a beginner or expert, Immix Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Immix Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Immix. Basic forecasting techniques help filter out the noise by identifying Immix Biopharma's price trends.Immix Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Immix Biopharma stock to make a market-neutral strategy. Peer analysis of Immix Biopharma could also be used in its relative valuation, which is a method of valuing Immix Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Immix Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Immix Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Immix Biopharma shares will generate the highest return on investment. By undertsting and applying Immix Biopharma stock market strength indicators, traders can identify Immix Biopharma entry and exit signals to maximize returns.
Immix Biopharma Risk Indicators
The analysis of Immix Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Immix Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting immix stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 4.75 | |||
| Semi Deviation | 4.04 | |||
| Standard Deviation | 6.18 | |||
| Variance | 38.19 | |||
| Downside Variance | 20.54 | |||
| Semi Variance | 16.29 | |||
| Expected Short fall | (6.12) |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Immix Biopharma
The number of cover stories for Immix Biopharma depends on current market conditions and Immix Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Immix Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Immix Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Immix Biopharma Short Properties
Immix Biopharma's future price predictability will typically decrease when Immix Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Immix Biopharma often depends not only on the future outlook of the potential Immix Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Immix Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 28.3 M | |
| Cash And Short Term Investments | 17.7 M |
Additional Tools for Immix Stock Analysis
When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.